Results 31 to 40 of about 1,341,600 (296)

Minimal disease activity, remission, and the long‐term outcomes of rheumatoid arthritis [PDF]

open access: yesArthritis Care & Research, 2007
AbstractObjectiveTo determine the prevalence of minimal disease activity (MDA) and remission in patients with rheumatoid arthritis (RA), to assess the effect of anti–tumor necrosis factor (anti‐TNF) therapy on MDA, and to determine the extent to which MDA status improves long‐term outcomes.MethodsUsing the Patient Activity Scale (PAS) as a surrogate ...
Wolfe, Frederick   +4 more
openaire   +3 more sources

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. [PDF]

open access: yesRMD Open, 2017
Objectives To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the ...
Mease PJ   +8 more
europepmc   +6 more sources

There is no relationship between Paraoxonase serum level activity in women with endometriosis and the stage of the disease: an observational study [PDF]

open access: yes, 2013
BACKGROUND: Endometriosis is a chronic condition whose pathophysiology is unknown, but there is evidence suggesting a link with oxidative stress. Paraoxonase is a serum enzyme which circulates associated with high-density lipoprotein (HDL).
Aline Amaro dos Santos   +8 more
core   +1 more source

The duration of remission and minimal disease activity after initiation and discontinuation of biological agents in patients with early psoriatic arthritis (data from the all-russian psoriatic arthritis registry)

open access: yesНаучно-практическая ревматология, 2019
Remission duration and minimal disease activity (MDA) during treatment with biological agents (BA) and after their discontinuation in patients with early psoriatic arthritis (PsA) have been insufficiently studied.Objective: to study the timing of the ...
E. Yu. Loginova   +3 more
doaj   +1 more source

Medium alkalization due to carbon metabolism is largely responsible for inhibition of bacterial growth by Vibrio cholerae supernatants [PDF]

open access: yes, 2017
Vibrio cholerae is the causative agent of the diarrheal disease cholera. Many Vibrio species secrete antimicrobial factors, though the identity of such a factor has not been determined for any V. cholerae strain.
Becker, Miranda
core   +1 more source

The BILAG-2004 systems tally-a novel way of representing the BILAG-2004 index scores longitudinally [PDF]

open access: yes, 2012
Objective. This was an exploratory analysis to develop a new way of representing BILAG-2004 system scores longitudinally that would be clinically meaningful and easier to analyse in comparison with multiple categorical variables. Methods.
Anisur Rahman   +30 more
core   +1 more source

EULAR Sjogren's syndrome disease activity index (ESSDAI):a user guide [PDF]

open access: yes, 2015
The EULAR Sj\uf6gren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS.
A. Tzioufas   +12 more
core   +2 more sources

Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice

open access: yesRheumatology and Therapy, 2023
Introduction Our aim was to investigate the efficacy and safety of upadacitinib (UPA) in patients with either oligo- or polyarticular active psoriatic arthritis (PsA) using routine clinical practice data from an observational, prospective, multicentre ...
Stephanie G. Werner   +10 more
doaj   +1 more source

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE

open access: yesНаучно-практическая ревматология, 2020
Objective: to evaluate the clinical efficacy and safety of the targeted synthetic disease-modifying anti-rheumatic drug (DMARD) tofacitinib (TOFA; Yakvinus®) in patients with active psoriatic arthritis (PsA) at 12 and 24 weeks after starting treatment ...
E. Yu. Loginova   +4 more
doaj   +1 more source

Toward understanding ambulatory activity decline in Parkinson disease [PDF]

open access: yes, 2015
BACKGROUND: Declining ambulatory activity represents an important facet of disablement in Parkinson disease (PD). OBJECTIVE: The primary study aim was to compare the 2-year trajectory of ambulatory activity decline with concurrently evolving facets of ...
Cavanaugh, James T.   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy